Form 4: Enliven Therapeutics CEO Executes Planned Stock Sale Under 10b5-1 Plan
Insider Transaction Report
Enliven Therapeutics, Inc. President and CEO, Samuel Kintz, reported the sale of 12,500 shares of common stock on July 17, 2025, through a pre-arranged Rule 10b5-1 trading plan.
Summary
- Samuel Kintz, President and CEO, and a Director of Enliven Therapeutics, Inc. (ELVN), reported the sale of 12,500 shares of the company's common stock.
- The transactions occurred on July 17, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kintz on November 15, 2024.
- The sales were conducted in three separate tranches at weighted average prices:
- 4,150 shares at $21.5787 per share (ranging from $21.26 to $22.17).
- 4,687 shares at $22.6925 per share (ranging from $22.28 to $23.26).
- 3,663 shares at $23.3706 per share (ranging from $23.285 to $23.595).
- Following these transactions, Samuel Kintz beneficially owns 940,392 shares of common stock indirectly through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While it's an insider sale, it was pre-planned under a 10b5-1 plan, which mitigates the negative perception often associated with insider selling. It does not reflect a change in company fundamentals or outlook.
Negatives
- The sale of 12,500 shares by a key executive and director could be perceived negatively by some investors as it reduces insider ownership.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of an insider stock transaction, common across all industries for publicly traded companies. It does not provide specific industry-related insights beyond the company's identity.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | The sales were conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a pre-arranged schedule for buying or selling shares to avoid accusations of insider trading. | 2024-11-15 | Enhances transparency and provides an affirmative defense against insider trading allegations for the reported transactions. |
Related Party Transactions
- The shares are held indirectly by The Kintz & Egan Trust Dated March 30, 2019, for which the reporting person, Samuel Kintz, serves as trustee. This constitutes an indirect beneficial ownership.
Stakeholder Impact
- Shareholders: The sale reduces the direct ownership stake of a key executive, which some investors might view as a slight negative, though the pre-planned nature mitigates this concern.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 2019-03-30 | Date of The Kintz & Egan Trust. |
| 2024-11-15 | Date the Rule 10b5-1 trading plan was adopted by Samuel Kintz. |
| 2025-07-17 | Date of the reported stock sales transactions. |
| 2025-07-21 | Date the Form 4 filing was signed. |
Keywords
Enliven Therapeutics, ELVN, Samuel Kintz, Insider Sale, Form 4, SEC Filing, 10b5-1 Plan, Common Stock, Executive Compensation, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.